| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $19,511,513 | 11 | 100 |
Sells | $0 | 0 | 0 |
| Fairmount Funds Management LLC | director | 1 | $6.01M | 0 | $0 | $6.01M |
| Lu Hongbo | director | 1 | $5M | 0 | $0 | $5M |
| MOULDER LEON O JR | Chief Executive Officer | 5 | $2.58M | 0 | $0 | $2.58M |
| SR ONE CAPITAL MANAGEMENT, LLC | 10 percent owner | 1 | $2.4M | 0 | $0 | $2.4M |
| ENRIGHT PATRICK G | director | 1 | $2.25M | 0 | $0 | $2.25M |
| Nunn Jason Raleigh | director | 1 | $1.2M | 0 | $0 | $1.2M |
| Xiao Ting | director | 1 | $77,600 | 0 | $0 | $77,600 |
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
Over the last 12 months, insiders at Zenas BioPharma, Inc. have bought $19.51M and sold $0 worth of Zenas BioPharma, Inc. stock.
On average, over the past 5 years, insiders at Zenas BioPharma, Inc. have bought $10.69M and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Fairmount Funds Management LLC (director) — $6.01M. Lu Hongbo (director) — $5M. MOULDER LEON O JR (Chief Executive Officer) — $2.58M.
The last purchase of 20,000 shares for transaction amount of $331,000 was made by MOULDER LEON O JR (Chief Executive Officer) on 2026‑01‑09.
| 2026-01-09 | MOULDER LEON O JR | Chief Executive Officer | 20,000 0.0491% | $16.55 | $331,000 | +21.62% | ||
| 2026-01-08 | MOULDER LEON O JR | Chief Executive Officer | 30,000 0.0711% | $16.30 | $489,000 | +20.36% | ||
| 2026-01-07 | MOULDER LEON O JR | Chief Executive Officer | 50,000 0.1194% | $16.38 | $819,000 | +14.63% | ||
| 2025-10-09 | SR ONE CAPITAL MANAGEMENT, LLC | 10 percent owner | 126,315 0.2053% | $19.00 | $2.4M | +26.08% | ||
| 2025-10-09 | ENRIGHT PATRICK G | director | 117,255 0.1925% | $19.19 | $2.25M | +26.08% | ||
| 2025-10-09 | Nunn Jason Raleigh | director | 63,158 0.1027% | $19.00 | $1.2M | +26.08% | ||
| 2025-10-07 | Fairmount Funds Management LLC | director | 316,219 0.6843% | $19.00 | $6.01M | +67.10% | ||
| 2025-10-07 | Lu Hongbo | director | 263,160 0.5695% | $19.00 | $5M | +67.10% | ||
| 2025-10-07 | MOULDER LEON O JR | See Remarks | 36,928 0.0877% | $20.85 | $769,949 | +67.10% | ||
| 2025-02-18 | MOULDER LEON O JR | Chief Executive Officer | 25,000 0.0572% | $6.67 | $166,750 | +136.09% | ||
| 2025-02-07 | Xiao Ting | director | 10,000 0.0237% | $7.76 | $77,600 | +99.87% | ||
| 2024-12-04 | MOULDER LEON O JR | Chief Executive Officer | 45,000 0.1064% | $9.98 | $449,100 | +4.42% | ||
| 2024-12-03 | MOULDER LEON O JR | Chief Executive Officer | 25,000 0.059% | $10.76 | $269,000 | -4.89% | ||
| 2024-11-19 | MOULDER LEON O JR | Chief Executive Officer | 2,500 0.0076% | $14.57 | $36,425 | -29.62% | ||
| 2024-11-18 | MOULDER LEON O JR | Chief Executive Officer | 7,500 0.0234% | $15.00 | $112,500 | -32.37% | ||
| 2024-09-13 | Lu Hongbo | director | 58,823 0.2079% | $17.00 | $999,991 | -43.29% |
| Fairmount Funds Management LLC | director | 2209025 5.2722% | $44.04M | 1 | 0 | |
| SR ONE CAPITAL MANAGEMENT, LLC | 10 percent owner | 1917895 4.5774% | $38.23M | 1 | 0 | |
| ENRIGHT PATRICK G | director | 1832669 4.374% | $36.53M | 1 | 0 | |
| Nunn Jason Raleigh | director | 1173395 2.8005% | $23.39M | 1 | 0 | |
| MOULDER LEON O JR | Chief Executive Officer | 366155 0.8739% | $7.3M | 9 | 0 | <0.0001% |
| Lu Hongbo | director | 321983 0.7685% | $6.42M | 2 | 0 | <0.0001% |
| Xiao Ting | director | 10000 0.0239% | $199,350.00 | 1 | 0 |
$28,907,358 | 35 | 41.41% | $943.33M | |
$94,912,877 | 34 | -7.15% | $756.17M | |
$41,446,394 | 27 | 12.91% | $802.06M | |
$7,598,498 | 27 | 34.68% | $851.59M | |
$169,638,586 | 22 | 30.82% | $736.35M | |
$59,102,045 | 17 | 8.52% | $736.71M | |
$133,809,976 | 13 | 31.29% | $881.18M | |
$92,357,691 | 12 | 87.24% | $780.77M | |
$278,247,340 | 12 | 58.08% | $862.5M | |
$1,229,070 | 10 | 23.53% | $865.69M | |
$11,541,901 | 10 | 8.07% | $775.33M | |
$1,580,951 | 9 | -14.18% | $914.65M | |
$160,798,946 | 8 | -3.92% | $825.23M | |
$1,229,547 | 7 | 11.98% | $829.86M | |
$40,959,889 | 5 | -1.88% | $994.46M | |
$51,588,185 | 5 | 19.18% | $731.26M | |
Zenas BioPharma, Inc. (ZBIO) | $1,148,916 | 3 | -35.10% | $835.27M |
$33,624,000 | 2 | -50.37% | $914.27M | |
$13,900 | 1 | -39.25% | $903.92M |
| Increased Positions | 35 | +43.75% | 2M | +6.92% |
| Decreased Positions | 30 | -37.5% | 2M | -5.01% |
| New Positions | 13 | New | 281,205 | New |
| Sold Out Positions | 8 | Sold Out | 647,997 | Sold Out |
| Total Postitions | 85 | +6.25% | 35M | +1.91% |
| Sr One Capital Management, Lp | $169,448.00 | 9.1% | 4.91M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $166,303.00 | 8.93% | 4.82M | +1M | +45.04% | 2025-09-30 |
| Enavate Sciences Gp, Llc | $129,767.00 | 6.97% | 3.76M | 0 | 0% | 2025-09-30 |
| Nea Management Company, Llc | $94,313.00 | 5.06% | 2.73M | 0 | 0% | 2025-09-30 |
| Novo Holdings A/S | $69,000.00 | 3.7% | 2M | -250,000 | -11.11% | 2025-09-30 |
| Fairmount Funds Management Llc | $65,302.00 | 3.51% | 1.89M | 0 | 0% | 2025-09-30 |
| Federated Hermes, Inc. | $64,233.00 | 3.45% | 1.86M | 0 | 0% | 2025-09-30 |
| Nvp Associates, Llc | $63,428.00 | 3.41% | 1.84M | 0 | 0% | 2025-09-30 |
| Deerfield Management Company, L.P. | $53,921.00 | 2.89% | 1.56M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $42,388.00 | 2.28% | 1.23M | +133,032 | +12.14% | 2025-09-30 |